Join our daily newsletter At The Bell to receive exclusive market insights
- Shares in healthcare stock Neurotech International (NTI) will stay grey until mid next week after the company entered back-to-back trading halts today
- At this stage, not much is known about why NTI requested the pause in trade
- However, the company has confirmed it’s gearing up to release initial results from a test tube experiment which analysed key cannabis strains
- Essentially, Neurotech is testing how cannabinoids can help treat neurological disorders like autism, epilepsy, and ADHD
- When it publishes its preliminary findings, Neurotech is also set to announce a capital raise, although the details of which are still unknown
- NTI shares last traded for 2.6 cents on October 28
Shares in healthcare stock Neurotech International (NTI) will stay grey until mid next week after the company entered back-to-back trading halts today.
At this stage, not much is known about why NTI requested the pause in trade. However, the company has confirmed it’s gearing up to release initial results from a test tube experiment which analysed key cannabis strains.
When it publishes its preliminary findings, Neurotech is also set to announce a capital raise.
While investors are yet to find out how much the company intends to raise — or even where the funding will go — more information should come to light by Wednesday, November 4.
In late September, NTI began it’s in vitro study, using immortalised human cells to analyse the effectiveness of key cannabis strains.
Essentially, Neurotech is testing how cannabinoids can help treat neurological disorders like autism, epilepsy, and ADHD.
It forms part of the healthcare stock’s broader mission, which is to create neurotechnology that can be accessed from the comfort of a patient’s home.
The study played out at three major laboratories, located at Monash University, the University of Wollongong, and RMIT.
At the time, Neurotech forecast all testing would be completed by next month. Ultimately, if the findings are substantial, the company can use the study to launch into clinical trials in the future.
NTI shares last traded for 2.6 cents on October 28.
